(PRWEB) December 10, 2013
Drugmaker Merck announced on Dec. 9 that it has agreed to pay about $28 million to settle Fosamax lawsuits stemming from claims that the osteoporosis drug caused patients’ jaws to deteriorate, or even “die,” according to Reuters. The Rottenstein Law Group LLP notes that the settlement involves more than 1,140 lawsuits in federal and state courts.
In order for the settlement to succeed, it requires 100 percent participation from the plaintiffs in the lawsuits, according to a Dec. 9 Reuters story.* The deadline to signal intent to file is Jan. 13. (In Re Fosamax Products Liability Litigation; 06-md-01789, U.S. District Court, Southern District of New York.)
“The decision to settle is not one to approach lightly,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “Plaintiffs in these Fosamax lawsuits need to consult with their qualified counsel to adequately and accurately assess their needs, and to determine if a settlement is the preferred outcome.”
The settlement applies only to those cases involving the deterioration or death of the jaw, according to Reuters. There are more than 4,000 Fosamax lawsuits involving femur fracture claims in state and federal courts, and those claimants are not eligible for a settlement, Reuters said.
The Rottenstein Law Group LLP encourages people to download a free informational brochure to learn more about the drug’s side effects and how to file a lawsuit.
About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com